# US 2026/0298938 A1 · Detection composition and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0298938 A1
- Document ID: US20260298938A1
- Status: Published application
- Kind: A1
- Application number: 18/996,440
- Filed: 2023-07-18
- Published: 2026-10-01
- Earliest claimed: 2022-07-18
- Assignees: GenAns Biotechnology Co., Ltd
- Applicants: Genans Biotechnology Co., Ltd
- Inventors: Rui LIN; Shilin ZHONG; Minmin LUO
- Web page: https://patentgrep.com/patent/US20260298938A1

## CPC

- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- G01N 33/6854: {Immunoglobulins}
- G01N 2458/10: Oligonucleotides as tagging agents for labelling antibodies
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided is a composition comprising an antibody linked with an oligonucleotide via a disulfide bond, wherein the oligonucleotide is specific for the antibody. Further provided is a kit comprising the same and the method for detecting one or more target in a sample by means of the composition.

## Claims

### Claim 1

A composition comprising an antibody linked with an oligonucleotide via a disulfide bond, wherein the oligonucleotide is specific for the antibody.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the disulfide bond is capable of being cut by a reducing agent, preferably by Tris(2-carboxyethyl)phosphine, dithiothreitol or beta-mercaptoethanol, so as to release the oligonucleotide.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the oligonucleotide comprises a hybridization chain reaction (HCR) initiator.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the oligonucleotide comprises a first barcode sequence which is specific for the antibody that it is linked therewith.

### Claim 5 (depends on 4)

The composition according to claim 4, wherein the oligonucleotide further comprises a unique molecular identifier (UMI) sequence, preferably, the UMI sequence comprises 10 to 20 nucleotides in length, more preferably 12 to 18 nucleotides in length.

### Claim 6 (depends on 4)

The composition according to claim 4, wherein the first barcode sequence comprises 5 to 15 nucleotides in length, preferably 5 to 10 nucleotides in length.

### Claim 7 (depends on 4)

The composition according to claim 4, wherein the oligonucleotide further comprises a second barcode sequence, which is specific for an information associated with a sample to be detected.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the antibody is a secondary antibody, which is selected from a group consisting of an anti-IgE antibody, an anti-IgM antibody, an anti-IgG antibody, an anti-IgA antibody, and an anti-IgD antibody,
preferably, the oligonucleotide-associated antibody is a nanobody.

### Claim 9 (depends on 8)

The composition according to claim 8, wherein the oligonucleotide-associated antibody specifically binds to an Fc region of the anti-IgE, anti-IgM, anti-IgG, anti-IgA or anti-IgD antibody.

### Claim 10 (depends on 1)

A kit for detecting a plurality of targets, comprising the composition of claim 1.

### Claim 11 (depends on 10)

The kit according to claim 10, wherein the kit comprises a plurality of oligonucleotide-associated antibodies each comprising an antibody associated with a specific HCR initiator, and one or more amplifiers,
preferably, each amplifier is conjugated with a detectable label selected from a group consisting of a chemical group, such as biotin, digoxigenin, acrydite, amine, succinimidyl ester, thiol, azide, TCO, Tetrazine, Alkyne and DBCO; and/or a fluorophore such as FITC, Cyanine dyes, Dylight fluors, Atto dyes, Janelia Fluor dyes, Alexa Fluor dyes.

### Claim 12 (depends on 1)

A method for detecting one or more target in a sample, comprising a step of a) incubating a first primary antibody with the composition as defined in claim 1, to form a complex having the first primary antibody associated with the composition.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the antibody of the composition is a secondary antibody, and the complex is formed by the interaction between the first primary antibody and the secondary antibody.

### Claim 14 (depends on 12)

The method according to claim 12, further comprising the steps of:
b) contacting the sample with the complex;
c) performing an amplification reaction to produce detectable amplified products; and
d) optionally, adding a reducing agent and incubating to cut the disulfide bond, and repeating the steps a) to c).

### Claim 15 (depends on 14)

The method according to claim 14, wherein the oligonucleotide comprises an HCR initiator, and the amplification reaction in step c) is a hybridization chain reaction.

### Claim 16 (depends on 12)

The method according to claim 12, further comprising the steps of:
b) contacting the sample with the complex;
c) adding a reducing agent and incubating to cut the disulfide bond;
d) collecting the specific oligonucleotides and performing an amplification reaction to detect the one or more targets; and
e) optionally, repeating steps a) to d),
wherein the oligonucleotide comprises a first barcode sequence.

### Claim 17 (depends on 12)

The method according to claim 12, wherein the method comprises, before step b), a step of incubating the sample with a support which is associated with a target-specific binding substance, to capture the target in the sample, preferably the target-specific binding substance is a second primary antibody or an antigen.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the support is selected from a group consisting of a microplate and magnetic beads.

### Claim 19 (depends on 12)

The method according to claim 12, wherein, in step a), one or more first primary antibodies incubate with one or more compositions each linked with an oligonucleotide specific for the antibody that it is linked therewith.

### Claim 20 (depends on 12)

The method according to claim 12, wherein the method is used for high-throughput sequencing.
